Assessment Of The Global Squamous Non-Small Cell Lung Cancer (NSCLC) Market (2026-2035): Therapeutic Types, Drug Classes, Treatment Lines, End-Users, Regions, Leading Players
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Squamous Non-Small Cell Lung Cancer Market by Therapeutic Type, Drug Class, Treatment Line, End-User, Geographical Regions, and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
The global squamous non-small cell lung cancer market is estimated to increase from USD 10 billion in the current year to USD 18.3 billion by 2035, representing a compound annual growth rate of 7.9% during the forecast period. Market expansion is being supported by the rising incidence of squamous non-small cell lung cancer (NSCLC), broader adoption of immunotherapy, increased investment in combination regimens and continued development of histology-specific oncology treatments.
Squamous Non-Small Cell Lung Cancer Market Growth and Trends
Squamous NSCLC remains closely associated with tobacco exposure and has fewer actionable driver alterations than lung adenocarcinoma. This biological profile limits the use of established precision medicines and contributes to an ongoing need for more effective treatment options. Pharmaceutical and biotechnology companies are increasingly addressing this therapeutic gap by developing clinical programs specifically for squamous histology.
Immunotherapy, administered alone or with chemotherapy, has become central to squamous NSCLC treatment. The expansion of PD-1 and PD-L1 checkpoint inhibitor indications across first-line and later-line settings is reshaping clinical practice and the competitive landscape. Late-stage studies are also becoming more histology-specific, as illustrated by BioNTech's Phase III gotistobart program, which resumed recruitment for patients with squamous NSCLC following different outcomes between squamous and non-squamous cohorts.
Key Market Growth Drivers
Rising disease incidence, persistent smoking-related risk and an expanding aging population are increasing the eligible patient pool. Tobacco use remains associated with a substantial proportion of cases, particularly in regions with high smoking prevalence. At the same time, checkpoint inhibitors such as pembrolizumab, nivolumab, atezolizumab and cemiplimab have improved outcomes compared with conventional chemotherapy for selected patients.
Regulatory approvals in first-line and second-line treatment settings have broadened the available therapeutic options. Pharmaceutical companies are also investing in regimens that combine immunotherapies with chemotherapy, targeted agents and novel immune modulators. These programs are intended to improve response durability, overcome treatment resistance and expand treatment eligibility.
Market Challenges
The limited availability of actionable genomic targets remains a major barrier to therapeutic innovation. Certain drugs used in non-squamous NSCLC, including bevacizumab and pemetrexed, are generally unsuitable for squamous histology because of safety concerns or limited clinical benefit. Variable PD-L1 expression, poorer survival outcomes compared with non-squamous disease and unequal access to advanced oncology care also constrain market development.
Addressing these challenges will require improved biomarker strategies, diversified drug development and wider access to testing and treatment. Next-generation bispecific antibodies, antibody-drug conjugates and emerging immuno-oncology candidates could create new options for patients who do not benefit from existing therapies.
Key Squamous NSCLC Market Insights
- Immunotherapy is becoming the treatment backbone across early-stage and advanced squamous NSCLC. Biomarker-guided treatment strategies are improving patient stratification and supporting more individualized care. Combination therapy development is accelerating as companies seek to improve survival and address resistance. Perioperative strategies, including neoadjuvant and adjuvant immunotherapy, are creating opportunities beyond metastatic disease. Merck entered a USD 700 million research and development funding agreement with Blackstone Life Sciences to support clinical development of the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan across indications that include NSCLC.
Market Segmentation and Leading Categories
The report evaluates the squamous non-small cell lung cancer market by therapeutic type, drug class, treatment line, end-user and geography. Therapeutic categories include immunotherapies, combination therapies, chemotherapy, targeted therapies and radiation therapies. Drug classes include PD-1 and PD-L1 inhibitors, platinum-based drugs, EGFR inhibitors, VEGF inhibitors and ALK inhibitors.
Immunotherapies currently account for the largest therapeutic share and are expected to record strong growth through 2035. Within the drug-class analysis, PD-1 and PD-L1 inhibitors lead the market because of their expanding clinical use and demonstrated survival benefits. Continued evaluation of checkpoint inhibitors in combination with chemotherapy and emerging agents is expected to enlarge the treatable population.
First-line treatment holds the largest share by treatment setting. Neoadjuvant therapy is forecast to expand rapidly as regulatory and clinical guideline support increases for immunotherapy-based regimens in resectable squamous NSCLC.
Hospitals remain the leading end-user segment because they serve as major centers for diagnosis, staging, multidisciplinary care and administration of complex oncology regimens. Specialty clinics are expected to grow rapidly as outpatient cancer services expand and more advanced treatments are delivered outside hospital settings.
Regional Market Outlook
North America currently dominates the global squamous NSCLC market, supported by advanced healthcare infrastructure, established reimbursement systems, extensive clinical research and a strong concentration of pharmaceutical and biotechnology companies. Asia-Pacific is projected to register the fastest growth through 2035, driven by rising disease incidence, improving cancer-care infrastructure and continued exposure to smoking and environmental risk factors in countries including China, India, Japan and South Korea.
Companies Featured in the Market Analysis
- AbbVie AstraZeneca BeiGene Bristol Myers Squibb Eli Lilly Merck Regeneron Pharmaceuticals Roche
Research Coverage
The report provides market forecasts under base-case, conservative and optimistic scenarios. It also assesses approved and late-stage therapies, clinical trial activity, developer pipelines, partnerships and competitive positioning. Drug profiles cover prominent therapies such as necitumumab, pembrolizumab, nivolumab, cemiplimab, ipilimumab and atezolizumab.
The analysis is supported by interviews with thoracic oncologists, medical oncologists, surgeons, pulmonologists, oncology nurse practitioners, academic researchers and drug development specialists. Market estimates use top-down epidemiology-based analysis and bottom-up drug-sales assessment to support opportunity sizing across therapies, treatment lines, end-users and regions.
Report Benefits
- Histology-specific analysis of the global squamous non-small cell lung cancer market. Detailed market sizing, forecasting and competitive intelligence through 2035. Assessment of drug pipelines, clinical trials, partnerships and emerging therapeutic opportunities. Actionable segmentation for drug developers, investors, distributors and commercialization partners. Complementary presentation insights and Excel data packs. Up to 15% complimentary content customization and an in-depth report walkthrough. Complimentary report update when the purchased report is more than six months old.
With immunotherapy use expanding, clinical pipelines diversifying and investment in squamous-specific drug development increasing, the global squamous non-small cell lung cancer market is positioned for sustained growth through 2035.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment